Professor Mileshkin is a medical oncologist and a clinical researcher with a particular interest in the treatment of lung and gynaecological cancers, as well as the supportive care of people affected by cancer. She also runs Australia’s only specialist clinic dedicated to the care of people affected by Cancer of Unknown Primary (CUP). She consults both at PeterMac in Parkville and at the Mercy Hospital for Women in Heidelberg.
Subsequent to training in medical oncology, she has completed a Masters of Bioethics as well as a translational research fellowship examining the role of predictive and prognostic factors in patients treated with thalidomide for multiple myeloma. Subsequently she has continued to expand her research portfolio and is currently involved in multiple clinical research projects involving people with gynaecological and lung cancers, plus carcinoma of unknown primary (CUP), as well as phase I trials in multiple tumour types.
Her current research focuses on:
1. Early and late phase clinical trials testing novel therapies for cancer
2. The supportive care of people affected by cancer
She is the international study chair for an international Australia-led government funded phase 3 trial of adjuvant therapy in locally advanced cervical cancer, as well as the principal investigator for multiple local and national trials. She is the clinical trials lead for Gynae-Oncology in the Parkville Cancer Clinical Trials Unit and is the Chair of the Gynaecological Tumour Group for Cancer Trials Australia as well as a core member of the PeterMac Department for Cancer Experiences Research. She is also very involved in the Australia New Zealand Gynaecological Oncology Group (ANZGOG) as a member of the board and the current chair of their Research Advisory Committee.